Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 3/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 10/20 | 0.37 |
| ▸ | CDK2 | P24941 | 10/20 | 0.37 |
| ▸ | CCNA1 | P78396 | 10/20 | 0.37 |
| ▸ | CDK1 | P06493 | 9/20 | 0.35 |
| ▸ | CCNB1 | P14635 | 9/20 | 0.35 |
| ▸ | MGMT | P16455 | 4/20 | 0.35 |
| ▸ | MPO | P05164 | 2/20 | 0.35 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1014919 | 0.76 | PDPK1 (0.39) | — | |
| SCHEMBL888386 | 0.73 | MGMT (0.30) | CCNA2CDK2CCNA1CDK1CCNB1 | |
| SCHEMBL5144478 | 0.73 | ADORA2A (0.44) | MGMTMPO | |
| SCHEMBL2908498 | 0.69 | CDK2 (0.54) | PIK3CACCNA2CDK2CCNA1 | |
| SCHEMBL10562546 | 0.68 | DHFR (0.44) | PIK3CA | |
| SCHEMBL7958023 | 0.66 | HRH4 (0.45) | — | |
| Methylguanine SCHEMBL231097 | 0.66 | CDK1 (0.69) | CCNA2CDK2CCNA1CDK1CCNB1 | |
| Methylguanine SCHEMBL29903462 | 0.66 | CDK1 (0.69) | CCNA2CDK2CCNA1CDK1CCNB1 | |
| SCHEMBL3418434 | 0.66 | CCNA2 (0.36) | PIK3CACCNA2CDK2CCNA1CDK1 | |
| SCHEMBL16828162 | 0.65 | CCNA2 (0.50) | PIK3CACCNA2CDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1975256-B1 | Modified oligonucleotides for mismatch discrimination | EPOCH BIOSCIENCES INC (US) | 2012-07-11 | — | — | EP | disclosed |
| EP-1261616-B1 | MODIFIED OLIGONUCLEOTIDES FOR MISMATCH DISCRIMINATION | EPOCH BIOSCIENCES INC (US) | 2010-08-18 | — | — | EP | disclosed |
| US-7751982-B2 | TM leveling methods | ELITECH HOLDING B.V. (NL) | 2010-07-06 | — | — | US | disclosed |
| EP-1995330-A1 | Modified oligonucleotides for mismatch discrimination | Epoch Biosciences, Inc. (US) | 2008-11-26 | — | — | EP | disclosed |
| EP-1975256-A1 | Modified oligonucleotides for mismatch discrimination | Epoch Biosciences, Inc. (US) | 2008-10-01 | — | — | EP | disclosed |
| EP-1944310-A2 | Modified oligonucleotides for mismatch discrimination | Epoch Biosciences, Inc. (US) | 2008-07-16 | — | — | EP | disclosed |
| EP-1427743-A4 | PROCESS FOR THE SYNTHESIS OF PYRAZOLOPYRIMIDINES | EPOCH BIOSCIENCES INC (US) | 2007-04-04 | — | — | EP | disclosed |
| US-20070060744-A1 | Process for the synthesis of pyrazolopyrimidines | EPOCH BIOSCIENCES, INC. (US) | 2007-03-15 | — | — | US | disclosed |
| US-7045610-B2 | Modified oligonucleotides for mismatch discrimination | EPOCH BIOSCIENCES, INC. (US) | 2006-05-16 | — | — | US | disclosed |
| US-20060014943-A1 | Process for the synthesis of pyrazolopyrimidines | EPOCH BIOSCIENCES, INC. (US) | 2006-01-19 | — | — | US | disclosed |
| US-6962991-B2 | Process for the synthesis of pyrazolopyrimidines | EPOCH BIOSCIENCES, INC. (US) | 2005-11-08 | — | — | US | disclosed |
| US-20050075491-A1 | TM leveling methods | EPOCH BIOSCIENCES, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| US-20040191824-A1 | Process for the synthesis of pyrazolopyrimidines | EPOCH BIOSCIENCES, INC. | 2004-09-30 | — | — | US | disclosed |
| EP-1427743-A2 | PROCESS FOR THE SYNTHESIS OF PYRAZOLOPYRIMIDINES | Epoch Biosciences, Inc. (US) | 2004-06-16 | — | — | EP | disclosed |
| US-6683173-B2 | CONJUGATING OLIGONUCLEOTIDE WITH 3-SUBSTITUTED PYRAZOLO(3,4-D)PYRIMIDINES AND/OR 5-SUBSTITUTED PYRIMIDINE MINOR GROOVE BINDER | EPOCH BIOSCIENCES, INC. | 2004-01-27 | — | — | US | disclosed |
| US-20030235822-A1 | Systems and methods for predicting oligonucleotide melting temperature (TmS) | EPOCH BIOSCIENCES, INC. | 2003-12-25 | — | — | US | disclosed |
| US-20030224359-A1 | TMLEVELING METHODS | EPOCH BIOSCIENCES, INC. | 2003-12-04 | — | — | US | disclosed |
| US-20030078413-A1 | Process for the synthesis of pyrazolopyrimidines | EPOCH BIOSCIENCES, INC. | 2003-04-24 | — | — | US | disclosed |
| WO-2003022859-A2 | PROCESS FOR THE SYNTHESIS OF PYRAZOLOPYRIMIDINES | EPOCH BIOSCIENCES, INC. (US) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078413-A1 | Process for the synthesis of pyrazolopyrimidines | DPYD, PNP, UMPS | PIK3CA 926/4885CCNA2 2019/4885CDK2 553/4885 |
| US-20050075491-A1 | TM leveling methods | RNGTT, TYMS, NT5C3B | PIK3CA 2315/4885CCNA2 4870/4885CDK2 4077/4885 |
| US-20060014943-A1 | Process for the synthesis of pyrazolopyrimidines | DPYD, PNP, UMPS | PIK3CA 926/4885CCNA2 2019/4885CDK2 553/4885 |
| US-20070060744-A1 | Process for the synthesis of pyrazolopyrimidines | DPYD, PNP, UMPS | PIK3CA 926/4885CCNA2 2019/4885CDK2 553/4885 |
| US-20030224359-A1 | TMLEVELING METHODS | PTBP3, RNGTT, DTYMK | PIK3CA 3455/4885CCNA2 4763/4885CDK2 3408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.